Global Burden of Sickle Cell Anaemia in Children under Five, 2010-2050: Modelling Based on Demographics, Excess Mortality, and Interventions by Piel, FB et al.
Global Burden of Sickle Cell Anaemia in Children under
Five, 2010–2050: Modelling Based on Demographics,
Excess Mortality, and Interventions
Fre´de´ric B. Piel1,2,3*, Simon I. Hay2, Sunetra Gupta1, David J. Weatherall4, Thomas N. Williams3,5,6
1 Evolutionary Ecology of Infectious Disease, Department of Zoology, University of Oxford, Oxford, United Kingdom, 2 Spatial Ecology and Epidemiology Group,
Department of Zoology, University of Oxford, Oxford, United Kingdom, 3Global Network for Sickle Cell Disease, Toronto, Ontario, Canada, 4Weatherall Institute of
Molecular Medicine, University of Oxford, Oxford, United Kingdom, 5 Kenya Medical Research Institute/Wellcome Trust Programme, Centre for Geographic Medicine
Research-Coast, Kilifi District Hospital, Kilifi, Kenya, 6Department of Medicine, Imperial College, St Mary’s Hospital, London, United Kingdom
Abstract
Background: The global burden of sickle cell anaemia (SCA) is set to rise as a consequence of improved survival in high-
prevalence low- and middle-income countries and population migration to higher-income countries. The host of
quantitative evidence documenting these changes has not been assembled at the global level. The purpose of this study is
to estimate trends in the future number of newborns with SCA and the number of lives that could be saved in under-five
children with SCA by the implementation of different levels of health interventions.
Methods and Findings: First, we calculated projected numbers of newborns with SCA for each 5-y interval between 2010
and 2050 by combining estimates of national SCA frequencies with projected demographic data. We then accounted for
under-five mortality (U5m) projections and tested different levels of excess mortality for children with SCA, reflecting the
benefits of implementing specific health interventions for under-five patients in 2015, to assess the number of lives that
could be saved with appropriate health care services. The estimated number of newborns with SCA globally will increase
from 305,800 (confidence interval [CI]: 238,400–398,800) in 2010 to 404,200 (CI: 242,500–657,600) in 2050. It is likely that
Nigeria (2010: 91,000 newborns with SCA [CI: 77,900–106,100]; 2050: 140,800 [CI: 95,500–200,600]) and the Democratic
Republic of the Congo (2010: 39,700 [CI: 32,600–48,800]; 2050: 44,700 [CI: 27,100–70,500]) will remain the countries most in
need of policies for the prevention and management of SCA. We predict a decrease in the annual number of newborns with
SCA in India (2010: 44,400 [CI: 33,700–59,100]; 2050: 33,900 [CI: 15,900–64,700]). The implementation of basic health
interventions (e.g., prenatal diagnosis, penicillin prophylaxis, and vaccination) for SCA in 2015, leading to significant
reductions in excess mortality among under-five children with SCA, could, by 2050, prolong the lives of 5,302,900 [CI:
3,174,800–6,699,100] newborns with SCA. Similarly, large-scale universal screening could save the lives of up to 9,806,000
(CI: 6,745,800–14,232,700) newborns with SCA globally, 85% (CI: 81%–88%) of whom will be born in sub-Saharan Africa. The
study findings are limited by the uncertainty in the estimates and the assumptions around mortality reductions associated
with interventions.
Conclusions: Our quantitative approach confirms that the global burden of SCA is increasing, and highlights the need to
develop specific national policies for appropriate public health planning, particularly in low- and middle-income countries.
Further empirical collaborative epidemiological studies are vital to assess current and future health care needs, especially in
Nigeria, the Democratic Republic of the Congo, and India.
Please see later in the article for the Editors’ Summary.
Citation: Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN (2013) Global Burden of Sickle Cell Anaemia in Children under Five, 2010–2050: Modelling Based on
Demographics, Excess Mortality, and Interventions. PLoS Med 10(7): e1001484. doi:10.1371/journal.pmed.1001484
Academic Editor: David Osrin, Institute for Global Health, United Kingdom
Received October 19, 2012; Accepted June 5, 2013; Published July 16, 2013
Copyright:  2013 Piel et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by funding from the Wellcome Trust (Biomedical Resources Grant #085406, PI: SIH) and the European Research Council
(Advanced Grant - DIVERSITY, PI: SG). SIH is funded by a Senior Research Fellowship from the Wellcome Trust (#095066). TNW is funded by a Senior Clinical
Fellowship from the Wellcome Trust (#091758). The funding agencies had no role in the design and conduct of the study; in the collection, management,
analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript. This paper is submitted with permission of the Director of
KEMRI.
Competing Interests: The authors have declared that no competing interests exist.
Abbreviations: CI, confidence interval; DRC, Democratic Republic of the Congo; GDPpc, gross domestic product per capita; GNIpc, gross national income per
capita; HbA, normal adult haemoglobin; HbS, sickle haemoglobin; SCA, sickle cell anaemia; U5m, under-five mortality; WHO, World Health Organization.
* E-mail: fred.piel@zoo.ox.ac.uk
PLOS Medicine | www.plosmedicine.org 1 July 2013 | Volume 10 | Issue 7 | e1001484
Introduction
While considerable efforts are currently being invested into
reducing the global burden of infectious diseases, particularly
malaria, tuberculosis, and HIV [1,2], the burden of birth defects
has largely been neglected [3–5]. It has recently been estimated
that more than 7 million babies are born each year with either a
congenital abnormality or a genetic disease [3]. Five disorders
constitute approximately 25% of these births, two of which,
haemoglobinopathy and glucose-6-phosphate dehydrogenase de-
ficiency, are monogenic diseases [6].
Amongst the haemoglobinopathies, sickle cell disease is by far
the largest public health concern. Sickle haemoglobin (HbS) is a
structural variant of normal adult haemoglobin (HbA) that is
inherited as an autosomal recessive Mendelian trait. While
heterozygote individuals are generally asymptomatic, homozygote
individuals (i.e., those with SCA) suffer from lifelong acute and
chronic complications [7]. Although sickle cell disorders include
not only SCA but also co-inherited haemoglobin S and
haemoglobin C (HbSC disease) or b-thalassaemia (HbS/b-
thalassaemia), the present study focuses exclusively on SCA, the
most severe and most common globally, accounting for an
estimated 83% of all newborns with sickle cell disorders [8].
Because of evolutionary selection due to malaria protection, the
highest frequencies of SCA are seen in tropical regions [9]. The
vast majority of newborns with SCA occur in low- and middle-
income countries. Without early diagnosis and treatment, most of
those affected die during the first few years of life, with reported
excess mortality reaching up to 92% [10]. Furthermore, infectious
diseases have a role in causing increased severity of SCA [11,12].
As low- and middle-income countries go through epidemiological
transition and improve hygiene, nutrition, and public health
policies and infrastructures, impressive reductions in overall infant
and childhood mortality have started to be observed [13–16].
Following population migration, SCA is now seen throughout
the world, as illustrated by the implementation of universal
screening programmes in the United States of America, in the
United Kingdom, and in French overseas territories. As it seems
likely that human migration will continue to increase with further
globalisation [17], the implementation of prevention measures,
including diagnosis and counselling, in low- and middle-income
countries will be of direct relevance for high-income countries.
Awareness about the clinical and economic burden of SCA is
rising, albeit slowly. In 2006, the World Health Organization
(WHO) recognised SCA as a global public health problem [18]. In
2010, the 63rd World Health Assembly adopted a resolution on
the prevention and management of birth defects, including sickle
cell disease and the thalassaemias. Finally, haemoglobinopathies
have been included in the most recent Global Burden of Diseases,
Injuries, and Risk Factors Study (the GBD 2010 study), which
aims at providing a comprehensive and systematic evidence-based
assessment of the burden of major diseases and injuries [19].
Quantitative studies provide essential evidence on which to base
public health decisions [20]. No such studies are currently
available for either SCA or other birth defects. We recently
estimated national allele frequencies for HbS using a contempo-
rary database of representative population surveys and a Bayesian
geostatistical framework [21]. By combining our estimates with
high-resolution data on crude birth rates and population densities,
we were able to estimate the global number of SCA-affected births
by country for 2010. Here, we use these estimates and
demographic projections to (i) assess the magnitude of the
expected increase in the global burden of SCA between 2010
and 2050, (ii) identify the countries most likely to be affected by
changes over the next decades, and (iii) provide quantitative
evidence to guide public health decisions at global, regional, and
national scales.
Methods
We conducted a quantitative investigation of the trends in the
number of newborns with SCA at national, regional, and global
scales. We then used a scenario-based approach that accounted for
differences between low-, middle-, and high-income countries.
Population movements are not considered in this study because of
their unpredictable nature and a lack of systematic data for their
prediction at the global level. Our model approach is summarised
in Figure 1, and a worked example showing how values were
calculated for Nigeria is presented in Table S1. A summary of the
assumptions made in this study is shown in Table 1.
Projected Number of Newborns with SCA
Our projections of the number of newborns with SCA are based
on the product of estimates of SCA frequency and projected birth
counts. For SCA, we have used the median and interquartile
range—the interval between the 25% and 75% quantiles of the
predicted posterior distribution—of our own frequency estimates
for 2010 [21]. Although only estimates of allele frequencies were
previously published, SCA frequencies were also calculated within
the Bayesian geostatistical framework used. For birth counts, we
used medium-, low-, and high-fertility variant projections for 5-y
periods between 2010 and 2050 from the 2010 revision of the
United Nations World Population Prospects [22]. The lower
bound of our confidence intervals (CIs) is based on the 25%
quantile for SCA estimates and the low-fertility variant for birth
counts. The higher bound of our CIs is based on the 75% quantile
for SCA estimates and the high-fertility variant for birth counts.
Data, with CIs, are presented for each country and for WHO
regions, HbS regions (as defined in [21]), and the world in Table
S2.
We generated cartograms of the number of newborns with SCA
in 2010, 2050, and over the period studied (2010–2050) (Figure 2)
using the Cartogram Geoprocessing Tool in ArcGIS 10.1 (Esri).
Cartograms are maps distorted proportionally to a variable other
than land area or geographical space [23,24]. They help to draw
attention to regions or countries that are overrepresented or
underrepresented when considering the particular variable
mapped.
We then ranked countries based on the magnitude of the
absolute change in the estimated median number of newborns
with SCA born between 2010 and 2050 (Table S2). Countries in
which the increase in the number of newborns with SCA was the
highest over the study period were assigned the lowest rank, while
countries in which the decrease in the number of newborns with
SCA was the highest over the study period were assigned the
highest rank. Ranks are shown in Table S2. For illustrative
purposes, we have limited this analysis to countries with a SCA
frequency higher than 0.001 and in which more than 100
newborns with SCA were estimated for 2010 (Figure 3A). We
applied a logarithmic transformation to further illustrate relative
changes (Figure 3B).
Lives Saved Scenarios
Because of the inheritance mechanism of the sickle cell gene,
changes in SCA allele frequency occur slowly, over generations
[23,24]. Studies conducted in Jamaica suggest that even in the
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absence of positive selection for heterozygotes the prevalence of
newborns with SCA will remain stable over very long periods of
time [25]. For the purposes of this analysis, we therefore assumed
that the prevalence of newborns with SCA will remain constant
during the period under study (2010–2050). Although few data are
available regarding SCA mortality, particularly in the areas of
highest prevalence, sharp reductions in SCA mortality in young
children following the implementation of specific health measures
are well documented in the US [26,27] and Jamaica [28,29].
Having calculated the baseline number of expected newborns with
SCA at global, regional, and national scales by 5-y intervals from
2010–2050, we then tested the following four scenarios assuming
the implementation in 2015 of the health measures described. (i)
Scenario 1 represents our best assessment of the current situation:
that in low- and middle-income countries, where the public health
infrastructures required for the diagnosis and care of children with
SCA are weak or absent, there is a 90% excess mortality among
children under five with SCA, based on data from Fleming et al.
[30] and Grosse et al. [10], but that in high-income countries with
good access to public health infrastructures, the excess mortality is
only 10%, based on data from Platt et al. [31]. Excess mortality is
calculated as the difference between the frequency of SCA in
newborns and in 5-y-olds, divided by the frequency of SCA in
newborns [10]. The number of surviving children with SCA by
age 5 y is therefore calculated as the number of newborns with
SCA multiplied by the survival rate in the overall under-five
population multiplied by the complement of the excess mortality
in children with SCA (12mexcess). (ii) Scenario 2 represents a
realistic short-term aim: to reduce the excess mortality to 50% in
low- and middle-income countries, as described in Simpore et al.
[32] and Grosse et al. [10] and to 5% in high-income countries,
reflecting basic improvements in general public health infrastruc-
tures in both sets of countries. It seems likely that such
improvements could be achieved by making penicillin prophylaxis
and screening programmes or prenatal diagnosis widely available,
[29]. (iii) Scenario 3 represents an optimistic aim that could
correspond to the implementation of specific health measures
targeting patients with SCA, such as widespread screening and the
provision of specialised clinics: to reduce excess mortality to 10%
in low- and middle-income countries and to eliminate it in high-
income countries, based on recent data from Quinn et al. and
Telfer et al. [33–35]. (iv) Scenario 4 represents the situation where
a 5% excess mortality is observed in low- and middle-income
countries and no excess mortality is observed in high-income
countries [33–35]. A summary of these scenarios is presented in
Table 2. By comparing Scenarios 2, 3, and 4 to Scenario 1, we
calculated the number of lives that could be saved for the different
levels of interventions considered.
Figure 1. Schematic overview of our model approach. Definition of variables: A, birth counts; B, frequency of SCA; C, mortality rate in under-
five children; D, number of births with SCA; E, excess mortality in under-five children with SCA; i, scenario number, from 1 to 4; X, number of infants
with SCA surviving; Y, number of lives of infants with SCA saved. U5, under five; UNPD, United Nations Population Division World Population
Prospects [22].
doi:10.1371/journal.pmed.1001484.g001
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Although the World Population Prospects [22] include migra-
tion data, only predictions of the net number of migrants are
presented. Such data do not allow quantifying future fluxes
between countries, which would be required for inclusion in the
present study.
We classified countries in four categories: low, middle low,
middle high, and high income, based on their 2010 gross
national income per capita (GNIpc), converted into US dollars,
as calculated by the World Bank (http://data.worldbank.org/
indicator/NY.GNP.PCAP.CD), and the World Bank income
group classes (low income, US$1,005 or less; lower middle
income, US$1,006–US$3,975; upper middle income,
US$3,976–US$12,275; and high income, US$12,276 or more).
For our mortality baseline, we used the U5m medium-, low-,
and high-fertility variant projections for 5-y periods between
2010 and 2050 from the 2010 revision of the UN World
Population Prospects [22]. Our economic indicator was the
projected gross domestic product per capita (GDPpc) as
published in the French Research Center in International
Economics’s BASELINE database (http://www.cepii.fr/
anglaisgraph/bdd/baseline.htm). Full data on U5m and GDPpc
are presented in Table S3.
The capacity of countries to manage a changing number of
newborns with SCA will depend on their current and future
economic status and on the overall survival of children. To
illustrate these changes, we created radar plots for each country
displaying (i) the number of newborns with SCA based on United
Nations medium-fertility variant projections, (ii) GDPpc, and (iii)
U5m in 2010 and in 2050 (Figure 4). Radar plots represent an easy
visualisation tool over time (within each country) and space
(between countries). Moreover, they provide an appropriate,
intuitive, and visually explicit ranking method for meta-analyses
[36]. Each axis of the radar plots was scaled independently based
on the minimum and maximum values of each indicator across all
countries.
Results
Projected Births and Newborns with SCA
The world population is expected to increase from 6,896 million
individuals in 2010 to 9,306 million in 2050 [22]. In many African
countries, where SCA frequency is the highest [21], the overall
number of births is expected to double during the period of time
considered in this study [22]. As a consequence, when assuming
constant gene frequencies, it is expected that the annual number of
newborns with SCA, estimated to be 305,800 (CI: 238,400–
398,800) globally in 2010, will likely increase by about one-third
by 2050 (404,200 [CI: 242,500 (+2%)–657,600 (+65%)]) (Table 3).
Globally, we estimated the overall number of births affected by
SCA between 2010 and 2050 to be 14,242,000 (CI: 9,923,600–
20,498,500).
Regionally, in 2010, an estimated 79% (242,200 [CI: 194,500
(82%)–302,000 (76%)]) of newborns with SCA occurred in sub-
Saharan Africa (Table 3; Figure 2A). This proportion is expected
to increase to 88% (353,500 [CI: 220,900 (91%)–546,700 (83%)])
by 2050 (Table 3; Figure 2B). In contrast, based on the UN
demographic projections, the proportion of newborns with SCA in
the other HbS regions (Eurasia, the Americas, and Arab-India),
apart from Southeast Asia, where SCA burden is very small, is
expected to decrease (Table 3).
In 2010, we estimated that three countries (Nigeria, India, and
the Democratic Republic of the Congo [DRC]) represented 57%
(175,200 [CI: 144,200 (60%)–214,000 (54%)]) of the annual
number of newborns with SCA globally (305,800 [CI: 238,400–
398,800]). By 2050, these countries are projected to represent
55% (219,400 [CI: 138,500–335,900] amongst 404,200 [CI:
242,500–657,600]). But while the relative contribution of Nigeria
is projected to increase from 30% (91,000 [CI: 77,900 (33%)–
106,100 (27%)]) to 35% (140,800 [CI: 95,500 (39%)–200,600
(31%)]), the DRC’s and India’s relative contributions are
expected to decrease from 13% (39,700 [CI: 32,600 (14%)–
Table 1. Summary of the assumptions and limitations of this study.
Assumption Notes/Limitations
We assumed that allele frequencies were constant over the study
period (2010–2050).
This is based on the slow kinetics of inherited disorders and on data from Jamaica
[25], but it neglects the influence of population migrations because of their
unpredictable nature.
We have assumed the implementation of specific health interventions
in 2015 to calculate the number of lives that could be saved.
Although some countries are currently considering implementing specific
interventions for SCA, it is impossible to predict when each country might
implement such interventions and to which extent.
We assumed that overall trends in the burden of SCA were driven
by newborns.
Data on the prevalence of SCA in adults is very limited, both in high- and low-
income countries. Moreover, few studies have investigated SCA survival in adults.
We assumed that it is possible to reduce excess mortality in under-five children to
zero in high-income countries and to 5% in low- and middle-income countries.
This is based on data from large-scale studies conducted in the United States, the
United Kingdom, and Jamaica, summarised in Quinn et al. [34].
We assumed that information on consanguinity was too crude to be incorporated. There is currently no global and comprehensive database on consanguinity.
We assumed that the implementation of specific interventions would lead
to an immediate reduction of the excess mortality in newborns with SCA.
This is supported by the proven efficacy of these interventions. Nevertheless, the
rapidity with which they might be implemented may vary widely between countries.
We assumed that focused care for children under 5 y would not detract
from care for others, including parents and older patients with SCA.
In the short term, improving the health of children under 5 y with SCA would increase
awareness about this disease, which would inevitably benefit adults and older
patients with SCA. In the long term, early diagnosis and appropriate health care helps
prevent many of the serious clinical complications observed in adults with SCA.
We assumed that data on the costs of implementing specific health
interventions were too limited, particularly in low- and middle-income
countries, to be incorporated into this study.
Although data on the costs of these health interventions are available from various
high-income countries, we could not find any published study presenting such data
for low- and middle-income countries.
doi:10.1371/journal.pmed.1001484.t001
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Figure 2. Cartograms of the estimated number of newborns with SCA per country. Cartograms of the estimated number of newborns with
SCA per country in 2010 (A), 2050 (B), and overall from 2010 to 2050 (C), based on data presented in Table S2. The estimates are based on the median
of the posterior predictive distribution for SCA frequencies generated by our Bayesian geostatistical model described in Piel et al. [21] and the
medium-fertility variant of the birth projections from the 2010 revision of the UN World Population Prospects [22].
doi:10.1371/journal.pmed.1001484.g002
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48,800 (12%)]) to 11% (44,700 [CI: 27,100 (11%)–70,500
(11%)]) and from 15% (44,400 [CI: 33,700 (15%)–59,100
(12%)]) to 8% (33,900 [CI: 15,900 (7%)–64,700 (10%)]),
respectively. Projections for the three most affected countries,
regions, and the world are plotted in Figure 5. Estimates for
2010, 2050, and 2010–2050 at national, regional, and global
scales are presented in Table S2 and plotted for selected
countries in Figure 3.
Figure 3. Country ranking based on estimated number of newborns with SCA in 2010 and 2050. Limited to countries for which the
estimated median SCA frequency in 2010 was higher than 0.001 and the estimated number of newborns with SCA in 2010 was higher than 100.
doi:10.1371/journal.pmed.1001484.g003
SCA Burden 2010-2050
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Estimated SCA Deaths and Lives Saved
By comparing the results of our scenarios with additional
interventions (Scenarios 2, 3, and 4) with the scenario based on
current practice (Scenario 1), we estimated the number of lives that
could be saved at different scales (Tables 4 and S1). A global
transition from Scenario 1 to Scenario 2 in 2015, would save
113,500 [CI: 85,100–152,900] newborns in 2015 and a total of
5,302,900 [CI: 3,174,800–6,699,100] newborns by 2050. A similar
transition to Scenario 3 would almost double the number of
newborns saved in 2015 and overall between 2015 and 2050.
Transitioning to Scenario 4 in 2015 would save 241,100 [CI:
180,800–324,900] newborns with SCA in 2015 and a total of
9,806,000 [CI: 6,745,800–14,232,700] by 2050.
The vast majority of SCA-affected newborn lives that could be
saved occur in sub-Saharan Africa. This is obvious when looking at
the annual estimates for 2010 and 2050, but even more striking when
looking at the overall calculations of lives lost over the 35-y projected
period from 2015 to 2050 (Table 4). Nigeria’s contribution to the
global burden of SCA is particularly important. Based on GNIpc,
more than 95% of the mortality burden among newborns with SCA
will fall to low- and middle-low-income countries (Table 4).
Our radar charts illustrate the different types of challenges that
are faced by different countries (Figures 4 and S1). For example, in
the DRC, the expected increase in the number of newborns with
SCA (from 39,800 [CI: 32,600–48,800] to 44,700 [CI: 27,100–
70,500]) will probably be accompanied by significant improve-
ments in survival (reduction of U5m from 180 to 75 per 1,000).
This will result in growing pressure on health care services during
a period in which the economic status of the country is not
expected to experience significant improvements (an increase in
the GDPpc from US$3,812 to only US$4,135) (Figure 4A; Table
S3). Nigeria will likely see a very large increase in the number of
newborns with SCA (from 91,000 [CI: 77,900–106,100] in 2010
to 140,800 [CI: 95,500–200,600] in 2050), while U5m is projected
to decrease from 141 to 49 per 1,000. This will aggravate the
national health burden of SCA to an extent that will be poorly
compensated by the projected increase in its GDPpc from
US$2,137 to US$9,015 (Figure 4B; Table S3). Conversely, the
situation seems a little less alarming in India, where we project that
the number of newborns with SCA will decrease from 44,400 (CI:
33,700–59,100) to 33,900 (CI: 15,900–64,700), while GDPpc will
increase by 6-fold (from US$3,062 to US$19,553) (Figure 4C;
Table S3), a situation that will potentially make the SCA burden
more manageable in that country.
Discussion
Despite slowly growing awareness about haemoglobinopathies,
and sickle cell disorders in particular, epidemiological data on the
Table 2. Summary of the level of public health infrastructure and excess mortality considered per income class and for each of the
four scenarios tested.
Scenario Low-/Middle-Income Countries (GNIpc#US$12,275) High-Income Countries (GNIpc.US$12,275)
General Level of Public Health
Infrastructures for Under-Five
Children with SCA
Excess Mortality in
Under-Five Children
with SCA
General Level of Public Health
Infrastructures for Under-Five
Children with SCA
Excess Mortality in Under-
Five Children with SCA
Scenario 1 Poor access to public health
infrastructures
90% Good access to public health
infrastructures
10%
Scenario 2 Good access to public health
infrastructures
50% Specific interventions for children
with SCA (e.g., diagnosis, treatment)
5%
Scenario 3 Specific interventions for children with
SCA (e.g., diagnosis, treatment)
10% Universal screening programme
(optimum)
0%
Scenario 4 Universal screening programme 5% Universal screening programme
(optimum)
0%
doi:10.1371/journal.pmed.1001484.t002
Figure 4. Radar plots of newborns with SCA, gross domestic product, and under-five mortality for the DRC, Nigeria, and India. Radar
plots for the DRC (A), Nigeria (B), and India (C). bSCA, estimated number of newborns with SCA.
doi:10.1371/journal.pmed.1001484.g004
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prevalence and burden of these disorders are still lacking
[6,21,37]. In difficult economic times, evidence-based studies to
support public health decisions and spending become increasingly
important [38]. It has been suggested that the burden of
haemoglobinopathies is going to increase over the coming decades
[6,39]. Such an increase is largely driven by two factors:
population growth and public health transition. This study is, to
our knowledge, the first attempt to quantify the magnitude of such
increases based on existing epidemiological estimates and demo-
graphic projections. Our study highlights major inequalities in the
current global distribution of newborns with SCA that are unlikely
to be reduced in the coming decades. Basic interventions targeted
to the most affected countries could save the lives of almost 10
million children born with SCA in the next 35 y.
The countries most affected face major challenges [37].
Currently, excess mortality in SCA patients in many low- and
middle-income countries—most of whom remain undiagnosed—is
extremely high, and SCA is often neglected in public health
policies. It is anticipated that as overall U5m begins to fall because
of improved nutrition and medical facilities, an increasing
proportion of children under 5 y with SCA will survive long
enough to reach medical attention. Public health improvements
(including widespread use of prophylactic penicillin and vaccina-
tion) will help an increasing proportion of these children to survive
through childhood and adulthood, and therefore to present for
diagnosis and treatment (e.g., hydroxyurea, hospitalisation,
transfusion) generating lifelong costs. The lack of interventions
will inevitably lead to a large burden on the public health
infrastructures and budgets of the countries most affected [40,41].
This needs to be acknowledged by policy makers so that adequate
planning can be used to save lives and keep treatment costs
manageable. In the short term, the priority in countries with a high
frequency of HbS is to identify affected births in order to provide
appropriate treatment. Cheap diagnostic methods are available for
HbS, and the cost-effectiveness of screening programmes has
already been demonstrated [42,43]. This study suggests that huge
numbers of lives could be saved in Nigeria [44–46], the DRC [47–
49], and India [50–52]. Some pilot screening programmes have
recently started in these countries, but nationwide programmes are
needed for a significant public health impact. In the long term, in
the absence of a definitive treatment for SCA, the best intervention
to reduce excess mortality caused by this disorder and to keep
public health costs associated with the follow-up care of SCA
patients through their lifetime manageable, especially in low-
income countries, is to avoid the births of affected newborns
[6,37]. A good knowledge of individual status, including carriers,
combined with a good education system about the inheritance
mechanism of HbS and the risks associated might help reduce the
number of newborns with SCA, but current evidence suggests that
prenatal diagnosis and genetic counselling is more effective
[40,53–55]. Because of population diaspora, increasing admixture,
and the absence of clinical symptoms in carriers, at-risk couples
Figure 5. Projections of estimated newborns with SCA between 2010 and 2050. Projections of estimated number of newborns with SCA (y-
axis) between 2010 and 2050 for the DRC, India, and Nigeria (in blue); HbS regions: Eurasia, the Americas, sub-Saharan Africa, Southeast Asia, and
Arab-India (in red; defined in Piel et al. [21]); and globally (in green). The dark-shaded areas represent the uncertainty in the demographic data. The
light-shaded areas show the uncertainty associated with our estimates of SCA frequency.
doi:10.1371/journal.pmed.1001484.g005
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include a much larger subset of the population than originally
estimated. Nevertheless, the idea that this disorder is confined to
individuals of African origins is still common amongst the medical
community, and this needs to change. Finally, it is essential to
implement systems for monitoring temporal and spatial changes in
the frequency of such disorders. In order to assess the efficiency of
implemented policies, such systems need to collect reliable data
from multiple health centres across a given country and to develop
appropriate analytical methods.
Despite its novelty, this study has several limitations. First, it
focuses only on newborns. Very few morbidity and mortality data
are available for SCA patients, particularly in low-income
countries, where deaths are usually attributed to other causes.
Until universal screening at the population level is implemented, it
is crucial to gather information on the mortality of SCA patients in
order to define the public health and economic costs associated
with HbS. It is likely that public health interventions such as those
described here would result in indirect benefits for other age
groups, but appropriate care for adults with SCA is something that
also needs to be considered. Second, we have assumed that the
implementation of specific interventions would lead to an
immediate reduction of the excess mortality in newborns with
SCA [27,29,56]. Although the benefits of these interventions have
been clearly demonstrated in studies conducted in high-income
countries, their implementation in low- and middle-income
countries, in which general health infrastructures are poor, might
be more challenging than assumed in this study. In addition, data
on the costs of implementing interventions for children with SCA
in low- and middle-income countries are currently lacking. Further
studies on issues such as these will be needed before the optimal
use of resources in different economic contexts can be defined.
Third, the clinical phenotype of sickle cell disorders is very broad,
being influenced by both genetic factors (e.g., a-thalassaemia or
high levels of haemoglobin F) and environmental factors (e.g.,
infections) [57]. Moreover, there is some evidence to suggest that
the Arab-Indian haplotype is milder than the African haplotypes
[58–60]. If this is confirmed by large-scale population surveys, the
economic burden in countries in which this haplotype is
predominant might be lower than that in countries where the
African haplotypes are prevalent. Current evidence was too sparse
to account for this in the present study. Fourth, consanguineous
marriages considerably increase the risk of having children with
SCA in areas where the allele frequency of HbS is high. Such
marriages are common in the Middle East and in various
population groups worldwide, but only limited data are available
globally [61,62]. Finally, we assumed constant allele frequencies
over the time period studied (40 y) [24,25]. This assumption,
which is based on the slow kinetics of inherited disorders, neglects
the influence of population migrations. The magnitude and
direction of past and current intra- or international population
movements, often caused by political instability, civil disturbances,
or environmental disasters, are difficult to assess. Allele frequencies
within one country can be highly heterogeneous, making
assumptions based only on nationality highly uncertain. Further-
more, it is almost impossible to predict future movements.
Accessing immigration data [63] and using mobile phone network
data [64,65] for international migrations would be possible, but
this is currently beyond the scope of this project.
Conclusion
Multiple warnings regarding the effect of epidemiological and
demographic transitions in low-income countries and their conse-
quences for SCA burden have been published [6,66]. By quantifying
this increase from 2010 to 2050 using evidence-based data and
identifying potential changes in the distribution of areas the most
affected, we hope (i) to highlight further the need for greater
awareness of SCA, appropriate public health policies, and funding; (ii)
to guide the implementation of appropriate policies; and (iii) to
provide a framework that could be applied to other birth defects. In
most countries, the burden of SCA has so far not been recognised. Its
long-term toll is nevertheless significant. These results highlight once
more the need for further epidemiological collaborative studies,
particularly in Nigeria, the DRC, and India, to define more
accurately the current and future health burden of SCA.
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Editors’ Summary
Background. More than seven million babies are born each
year with a structural or functional abnormality. Although
some birth defects are caused by environmental factors,
many are caused by the inheritance of a defective gene. One
common inherited birth defect is sickle cell anemia (SCA).
SCA arises when a baby inherits the gene for sickle
hemoglobin (HbS), a structural variant of normal adult
hemoglobin (HbA, the protein in the disc-shaped red blood
cells that carry oxygen round the body), from both its
parents. Every cell in the human body contains two full sets
of genes, and babies inherit one set of genes from each
parent. The parents usually each have one HbS gene and one
HbA gene, and are unaffected. However, the red blood cells
of their offspring who inherit two copies of HbS develop a
sickle (crescent) shape. Sickle cells can block blood vessels in
the limbs and organs and have a shorter lifespan than
normal red blood cells, which causes anemia. Together,
these changes can cause acute pain and organ damage, and
can increase the risk of severe infections. SCA can be
prevented by prenatal diagnosis and managed by interven-
tions such as the provision of antibiotics and vaccination to
prevent infections.
Why Was This Study Done? Without early diagnosis and
treatment, children with SCA often die within the first few
years of life. Having one copy of the HbS gene provides
people with protection from malaria, therefore SCA occurs
mainly in low- and middle-income countries in tropical
regions, where early diagnosis and treatment is often
unavailable. Recent improvements in overall infant and
childhood survival in these countries and population
migration to higher-income countries mean that the global
burden of SCA is likely to increase over the coming decades.
To date, no one has tried to quantify this increase, although
this information is needed to guide decisions on public
health spending. In this modeling study, the researchers
assess the size of the expected global burden of SCA
between 2010 and 2050 in children under five years old and
estimate the number of newborn lives that might be saved
by implementation of various health interventions.
What Did the Researchers Do and Find? The researchers
used estimates of national SCA frequencies and data on
projected birth rates to calculate that the number of
newborns with SCA will increase from about 305,800 in
2010 to about 404,200 in 2050. They estimated that Nigeria,
the Democratic Republic of Congo (DRC), and India
accounted for 57% of newborns with SCA in 2010, and that
Nigeria and the DRC will probably still be the countries most
in need of policies for the prevention and management of
SCA in 2050. The researchers then assessed how many
newborns might be saved by the implementation of various
health measures in 2015 that affect excess mortality (the
difference between the frequency of SCA in newborns and in
five-year-olds divided by the frequency of SCA in newborns)
among children born with SCA. Implementation of prenatal
diagnosis and newborn screening programs, and provision
of antibiotics and vaccinations (interventions assumed by the
researchers to reduce excess mortality from 90% to 50% in
low- and middle-income countries and from 10% to 5% in
high-income countries) could prolong the life of more than
five million newborns with SCA by 2050. Implementation of
universal screening and provision of other specific measures
predicted to reduce excess mortality to 5% and 0% in low-to-
middle-income countries and high-income countries, respec-
tively, could save nearly ten million lives by 2050.
What Do These Findings Mean? In estimating the global
burden of SCA in children under five years old between 2010
and 2050 and the number of newborn lives that could be
saved by implementation of health interventions, the
researchers made numerous assumptions reflected in the
uncertainty associated with the projections. For example,
they assumed that implementation of specific interventions
would lead to an immediate reduction of excess mortality in
newborns with SCA. The study’s findings confirm, however,
that the global burden of SCA is increasing and indicate that
the implementation of specific interventions could extend
the lives of millions of newborns with SCA. Although further
studies are needed to assess the current and future health
care needs of children with SCA, these findings highlight the
need to develop and implement national public health
planning and funding policies for SCA, particularly in low-
and middle-income countries.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001484.
N This study is further discussed in a PLOS Medicine
Perspective by Edward Fottrell and David Osrin
N The US National Heart, Lung, and Blood Institute provides
detailed information (including personal stories) about
sickle cell anemia (in English and Spanish)
N The UK National Health Service Choices website also
provides detailed information and a personal story about
sickle cell anemia
N The Sickle Cell Society, a UK-based not-for-profit organiza-
tion, provides information for patients and carers and
includes a children’s website
N The World Health Organization has a factsheet on sickle
cell anemia and other inherited hemoglobin diseases (in
several languages)
N MedlinePlus provides links to further resources about sickle
cell anemia (in English and Spanish)
N The Malaria Atlas Project provides epidemiological infor-
mation on the inherited blood disorders (including sickle
cell anemia) that affect our response to malaria infection
N The Global Sickle Cell Disease Network is a portal bringing
together leading sickle cell disease researchers and
clinicians from high-, middle-, and low-income countries
to form a network
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